Note R - Merger (Details Textual)							1 Months Ended		3 Months Ended			12 Months Ended
	Nov. 22, 2023 shares	Nov. 17, 2023 USD ($) $ / shares shares	Aug. 30, 2023 USD ($) shares	Jun. 16, 2023 USD ($) $ / shares shares	Jan. 31, 2023 USD ($) shares	Mar. 14, 2022 USD ($)	Dec. 31, 2023 USD ($)	Nov. 30, 2023 shares	Sep. 30, 2023 USD ($)	Jun. 30, 2023 USD ($)	Mar. 31, 2023 USD ($)	Dec. 31, 2023 USD ($) shares	Dec. 31, 2022 USD ($)	Oct. 31, 2023 USD ($)
Stock Issued During Period, Shares, Acquisitions (in shares) | shares								1,382,489				7,530,509
Stock Issued During Period, Value, New Issues												$ 6,106,000
Net Income (Loss) Attributable to Parent									$ (10,365,000)	$ (2,573,000)	$ (13,217,000)	(46,049,000)	$ (26,772,000)
The Investor Warrant [Member]
Stock Issued During Period, Shares, New Issues (in shares) | shares	917,934							917,934
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares	2,920,306							2,920,306
SWK Loans [Member]
Payments to Acquire Notes Receivable			$ 12,000,000		$ 12,000,000
Stock Issued During Period, Shares, Acquisitions (in shares) | shares			98,683		98,683
Marathon Convertible Notes [Member]
Stock Issued During Period, Shares, Acquisitions (in shares) | shares				2,171,038
Asset Acquisition, Share Price (in dollars per share) | $ / shares				$ 5.0667
Asset Acquisition, Consideration Transferred				$ 11,000,000
SWK Loans and Marathon Notes [Member]
Payments to Acquire Notes Receivable		$ 12,000,000
Stock Issued During Period, Shares, Acquisitions (in shares) | shares		2,270,000
Asset Acquisition, Consideration Transferred, Equity Interest Issued and Issuable		$ 11,500,000
VWAP, Consecutive Trading Days (Year)		20 years
Nantahala Note [Member]
Debt Instrument, Face Amount		$ 5,000,000	$ 5,000,000		$ 5,000,000
Acer Therapeutics Inc [Member] | License Agreement and Termination Agreement [Member] | Relief [Member]
Maximum Royalty Percentage			20.00%
Upfront Payment			$ 10,000,000
Addiitonal Payment on First Anniversary			1,500,000
Maximum Royalty Obligation			$ 45,000,000
Acer Therapeutics Inc [Member] | License Agreement and Termination Agreement [Member] | Relief [Member] | Europe [Member]
Maximum Royalty Percentage			10.00%
Acer Therapeutics Inc [Member] | License Agreement and Termination Agreement [Member] | Relief [Member] | Worldwide, Excluding Europe [Member]
Maximum Royalty Percentage			10.00%
Acer Therapeutics Inc [Member] | SWK Loans [Member]
Proceeds from Issuance of Long-Term Debt					$ 7,000,000	$ 6,500,000
Maximum [Member] | Acer Therapeutics Inc [Member] | License Agreement and Termination Agreement [Member] | Relief [Member]
Contractual Obligation			$ 56,500,000
Bridge Loan [Member]
Financing Receivable, Maximum Limit			18,000,000											$ 18,000,000
Bridge Loan [Member] | Minimum [Member]
Financing Receivable, Maximum Limit			16,500,000
Acer Therapeutics Inc [Member]
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable, Conversion Ratio		0.121
Business Acquisition, Share Price (in dollars per share) | $ / shares		$ 0.0001
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High		$ 76,000,000
Business Combination, Consideration Transferred		$ 72,600,000
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in shares) | shares		2,960,000
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable		$ 12,800,000
Business Combination, Contingent Consideration, Liability		8,500,000					$ 7,262,000					7,262,000	$ 0
Repayments of Notes Payable		$ 1,000,000
Revenues							42,000
Net Income (Loss) Attributable to Parent							$ (6,800,000)
Business Combination, Acquisition Related Costs												2,200,000
Gain (Loss) on Contingent Consideration, Change in Fair Value												$ 1,300,000
Acer Therapeutics Inc [Member] | Acer Warrants [Member]
Stock Issued During Period, Shares, New Issues (in shares) | shares		900,000
Stock Issued During Period, Value, New Issues		$ 4,000,000
Acer Therapeutics Inc [Member] | Bridge Loan [Member]
Business Combination, Consideration Transferred, Other		$ 17,800,000	$ 16,500,000